These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 33164614)
21. Characteristics of rheumatoid arthritis with immunodeficiency-associated lymphoproliferative disorders to regress spontaneously by the withdrawal of methotrexate and their clinical course: A retrospective, multicenter, case-control study. Kuramoto N; Saito S; Fujii T; Kaneko Y; Saito R; Tanaka M; Takada H; Nakano K; Saito K; Sugimoto N; Sasaki S; Harigai M; Suzuki Y Mod Rheumatol; 2022 Jan; 32(1):24-31. PubMed ID: 33496194 [TBL] [Abstract][Full Text] [Related]
22. Methotrexate-related Epstein-Barr virus-associated lymphoproliferative disorder occurring in the gingiva of a patient with rheumatoid arthritis. Ishida M; Hodohara K; Yoshii M; Okuno H; Horinouchi A; Nakanishi R; Harada A; Iwai M; Yoshida K; Kagotani A; Yoshida T; Okabe H Int J Clin Exp Pathol; 2013; 6(10):2237-41. PubMed ID: 24133604 [TBL] [Abstract][Full Text] [Related]
23. Clinicopathological analysis of methotrexate-associated lymphoproliferative disorders: Comparison of diffuse large B-cell lymphoma and classical Hodgkin lymphoma types. Gion Y; Iwaki N; Takata K; Takeuchi M; Nishida K; Orita Y; Tachibana T; Yoshino T; Sato Y Cancer Sci; 2017 Jun; 108(6):1271-1280. PubMed ID: 28380678 [TBL] [Abstract][Full Text] [Related]
24. Diffuse Large B-cell Lymphoma with Adrenal Involvement Presenting as Other Iatrogenic Immunodeficiency-associated Lymphoproliferative Disorders: Sustained Remission with Methotrexate Termination Alone in Two Cases. Yasuda H; Ando J; Yoshida S; Ota Y; Komatsu N; Ando M Intern Med; 2023 Feb; 62(4):601-604. PubMed ID: 35793959 [TBL] [Abstract][Full Text] [Related]
25. Methotrexate-related lymphoproliferative disorder of the stomach in a patient with rheumatoid arthritis: a case of disease regression after methotrexate cessation. Ikeda K; Nakamura T; Kinoshita T; Fujiwara M; Uose S; Someda H; Miyoshi T; Io K; Nagai K Clin J Gastroenterol; 2016 Feb; 9(1):17-21. PubMed ID: 26733461 [TBL] [Abstract][Full Text] [Related]
26. The prognostic value of positron emission tomography/computed tomography in rheumatoid arthritis patients with methotrexate-associated lymphoproliferative disorders. Takanashi S; Nakazato T; Aisa Y; Ito C; Arakaki H; Osada Y; Hirano M; Mori T Ann Hematol; 2018 Sep; 97(9):1611-1618. PubMed ID: 29713747 [TBL] [Abstract][Full Text] [Related]
27. Lymphoproliferative disorders in patients with rheumatoid arthritis in the era of widespread use of methotrexate: A review of the literature and current perspective. Harigai M Mod Rheumatol; 2018 Jan; 28(1):1-8. PubMed ID: 28758827 [TBL] [Abstract][Full Text] [Related]
28. Clinicopathological features of clinical methotrexate-related lymphoproliferative disorders. Tokuhira M; Saito S; Suzuki K; Higashi M; Momose S; Shimizu T; Mori T; Kimura Y; Amano K; Okamoto S; Takeuchi T; Tamaru JI; Kizaki M Leuk Lymphoma; 2019 Oct; 60(10):2508-2515. PubMed ID: 30947579 [TBL] [Abstract][Full Text] [Related]
29. The clinical impact of absolute lymphocyte count in peripheral blood among patients with methotrexate - associated lymphoproliferative disorders. Tokuhira M; Tanaka Y; Takahashi Y; Kimura Y; Tomikawa T; Anan T; Watanabe J; Sagawa M; Higashi M; Momose S; Amano K; Tabayashi T; Nakaseko R; Tamaru JI; Kizaki M J Clin Exp Hematop; 2020 Jun; 60(2):41-50. PubMed ID: 32404570 [TBL] [Abstract][Full Text] [Related]
30. Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders. Tokuhira M; Tamaru JI; Kizaki M J Clin Exp Hematop; 2019; 59(2):72-92. PubMed ID: 31257348 [TBL] [Abstract][Full Text] [Related]
31. Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study. Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Nagai K; Son Y; Amuro H; Onishi A; Jinno S; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M Clin Rheumatol; 2020 Sep; 39(9):2563-2572. PubMed ID: 32162152 [TBL] [Abstract][Full Text] [Related]
32. A case of multiple hepatic lesions associated with methotrexate-associated lymphoproliferative disorder. Matsumoto R; Numata K; Doba N; Hara K; Chuma M; Fukuda H; Nozaki A; Tanaka K; Ishii Y; Maeda S J Med Ultrason (2001); 2016 Oct; 43(4):545-51. PubMed ID: 27577564 [TBL] [Abstract][Full Text] [Related]
33. Spontaneous regression of breast lymphoproliferative disorders after withdrawal of methotrexate in rheumatoid arthritis patients with Epstein-Barr virus infection: a case report and review of the literature. Ogawa A; Nakagawa T; Kumaki Y; Hosoya T; Oda G; Mori M; Fujioka T; Kubota K; Onishi I; Uetake H J Med Case Rep; 2022 Feb; 16(1):49. PubMed ID: 35125110 [TBL] [Abstract][Full Text] [Related]
34. Clinicopathological findings, prognosis, and Epstein-Barr virus infection in rheumatoid arthritis patients with other iatrogenic immunodeficiency-associated T- and NK-cell lymphoproliferative disorders. Kimura S; Oshiro Y; Iwasaki H; Kadowaki M; Ogata M; Daa T; Sakata T; Kawauchi S; Wang Z; Takamatsu Y; Takeshita M BMC Cancer; 2022 Dec; 22(1):1342. PubMed ID: 36544095 [TBL] [Abstract][Full Text] [Related]
35. Mature T/NK-cell lymphoproliferative disease and Epstein-Barr virus infection are more frequent in patients with rheumatoid arthritis treated with methotrexate. Kondo S; Tanimoto K; Yamada K; Yoshimoto G; Suematsu E; Fujisaki T; Oshiro Y; Tamura K; Takeshita M; Okamura S Virchows Arch; 2013 Apr; 462(4):399-407. PubMed ID: 23494713 [TBL] [Abstract][Full Text] [Related]
36. Overall survival and post-spontaneous regression relapse-free survival of patients with lymphoproliferative disorders associated with rheumatoid arthritis: a multi-center retrospective cohort study. Saito R; Tanaka M; Ito H; Kuramoto N; Fujii T; Saito S; Kaneko Y; Nakano K; Saito K; Takada H; Sugimoto N; Sasaki S; Harigai M; Suzuki Y Mod Rheumatol; 2022 Jan; 32(1):50-58. PubMed ID: 33336615 [TBL] [Abstract][Full Text] [Related]
37. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438 [TBL] [Abstract][Full Text] [Related]
38. Epstein-Barr virus-related lymphoma in rheumatoid arthritis: implications for long-term usage of immunosuppressive drugs and review of the literature. He J; Williamson L; Cai K; Wong P; Sturgess A; Taper J; Manolios N Intern Med J; 2022 Oct; 52(10):1717-1723. PubMed ID: 34028145 [TBL] [Abstract][Full Text] [Related]
39. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study. Ebina K; Hashimoto M; Yamamoto W; Hirano T; Hara R; Katayama M; Onishi A; Nagai K; Son Y; Amuro H; Yamamoto K; Maeda Y; Murata K; Jinno S; Takeuchi T; Hirao M; Kumanogoh A; Yoshikawa H Arthritis Res Ther; 2019 Apr; 21(1):91. PubMed ID: 30971306 [TBL] [Abstract][Full Text] [Related]
40. Methotrexate-associated lymphoproliferative disorder in the stomach and duodenum: a case report. Toyonaga H; Fukushima M; Shimeno N; Inokuma T BMC Gastroenterol; 2019 Apr; 19(1):62. PubMed ID: 31023238 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]